Long-Term Outcomes of Stereotactic Radiosurgery for Pineocytomas: An International Multicenter Study

医学 放射外科 期限(时间) 医学物理学 多中心研究 梅德林 放射科 外科 放射治疗 随机对照试验 天文 政治学 物理 法学
作者
Andréanne Hamel,Jean-Nicolas Tourigny,Ajay Niranjan,L. Dade Lunsford,Zhishuo Wei,Priyanka Srinivasan,Roman Liščák,Jaromír May,Nuria Martínez Moreno,Roberto Martínez Álvarez,Cheng‐Chia Lee,Huai‐Che Yang,Manjul Tripathi,Narendra Kumar,Elad Mashiach,Douglas Kondziolka,Robert G. Briggs,Cheng Yu,Gabriel Zada,Andrea Franzini,Guido Pecchioli,Gregory Bowden,Sam Dayawansa,Jason P. Sheehan,David Mathieu
出处
期刊:Neurosurgery [Lippincott Williams & Wilkins]
标识
DOI:10.1227/neu.0000000000003261
摘要

BACKGROUND AND OBJECTIVES: Pineocytomas are grade 1 tumors arising from the pineal parenchyma. Gross total resection can potentially cure these benign lesions but can be associated with morbidity. This study was designed to provide multi-institutional data to evaluate the results of stereotactic radiosurgery (SRS) for pineocytomas. METHODS: Centers participating in the International Radiosurgery Research Foundation were asked to review their database and provide data for patients who had SRS for histology confirmed grade 1 pineocytomas, for whom clinical and imaging follow-up of at least 6 months was available. RESULTS: In total, 38 patients underwent SRS as part of the management of a pineocytoma. The median age at SRS was 39 years (range 8-76). SRS was performed as primary approach in 68%, adjuvant after partial resection 19%, and at recurrence in 13% of patients. The median margin dose was 15 Gy (range 11-25 Gy). The median treatment volume was 3.35 cc (range 0.1-17.9 cc). Local tumor control was achieved in 92% of patients, with a mean actuarial progression-free survival of 21.6 years (median not reached). At last follow-up, 82% were still controlled, 8% had local recurrence, and 10% had cerebrospinal fluid dissemination. Tumor control was significantly better when SRS was used as primary care compared with the adjuvant or recurrent setting ( P = .016). Five patients (13%) died during follow-up, all from tumor progression. The actuarial mean survival duration was 24.3 years, with a 5-year survival rate of 91%, and an estimated rate of 76% at 29 years. Larger tumor volume at SRS was found to be correlated to increased risk of death ( P = .045). Transient symptomatic adverse radiation effects were observed in 4 patients (11%). CONCLUSION: SRS appears safe and effective for the management of pineocytomas. Long-term tumor control is achieved in most cases. SRS can be offered to selected patients as an alternative to surgical resection.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
浮游应助成佳木采纳,获得10
刚刚
Owen应助曦曦采纳,获得10
1秒前
1秒前
1秒前
1秒前
12131完成签到,获得积分20
2秒前
2秒前
2秒前
蓝色斑马发布了新的文献求助10
3秒前
烟花完成签到,获得积分10
3秒前
大胆傲芙发布了新的文献求助10
4秒前
马夋完成签到,获得积分10
4秒前
科研通AI2S应助健忘千雁采纳,获得10
4秒前
Jiang完成签到,获得积分10
4秒前
pups发布了新的文献求助80
4秒前
Ww发布了新的文献求助10
5秒前
烂漫的煎饼完成签到 ,获得积分10
5秒前
chixueqi完成签到,获得积分10
5秒前
6秒前
6秒前
6秒前
6秒前
鸭子发布了新的文献求助10
7秒前
7秒前
7秒前
7秒前
majf发布了新的文献求助10
7秒前
8秒前
小蘑菇应助咕嘟采纳,获得10
8秒前
8秒前
2222完成签到,获得积分10
9秒前
sen发布了新的文献求助10
9秒前
Swift168_YY发布了新的文献求助10
9秒前
哈尼完成签到,获得积分10
10秒前
弓长发布了新的文献求助30
10秒前
Ava应助顺利的奇异果采纳,获得10
10秒前
ZephyrZY完成签到,获得积分10
10秒前
情怀应助顾顾采纳,获得10
10秒前
小满完成签到,获得积分10
10秒前
sy1639发布了新的文献求助10
11秒前
高分求助中
Incubation and Hatchery Performance, The Devil is in the Details 2000
Pipeline and riser loss of containment 2001 - 2020 (PARLOC 2020) 1000
Comparing natural with chemical additive production 500
The Leucovorin Guide for Parents: Understanding Autism’s Folate 500
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 500
A Manual for the Identification of Plant Seeds and Fruits : Second revised edition 500
The Social Work Ethics Casebook: Cases and Commentary (revised 2nd ed.) 400
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 内科学 生物化学 物理 计算机科学 纳米技术 遗传学 基因 复合材料 化学工程 物理化学 病理 催化作用 免疫学 量子力学
热门帖子
关注 科研通微信公众号,转发送积分 5204680
求助须知:如何正确求助?哪些是违规求助? 4383701
关于积分的说明 13650154
捐赠科研通 4241580
什么是DOI,文献DOI怎么找? 2326956
邀请新用户注册赠送积分活动 1324605
关于科研通互助平台的介绍 1276907